Cargando…

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma

Metastatic pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors associated with poor prognosis and limited therapeutic options. Recent advances in oncology-related immunotherapy, specifically in targeting of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) path...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadrava Vanova, Katerina, Uher, Ondrej, Meuter, Leah, Ghosal, Suman, Talvacchio, Sara, Patel, Mayank, Neuzil, Jiri, Pacak, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691952/ https://www.ncbi.nlm.nih.gov/pubmed/36439433 http://dx.doi.org/10.3389/fonc.2022.1045517

Ejemplares similares

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

PSAT089 Lack of Effect of Metformin in Murine Pheochromocytoma Model
por: Ghayee, Hans K, et al.
Publicado: (2022)

PSUN27 Largest Cohort of Cervical Spine Metastases of Pheochromocytoma/Paraganglioma in the Setting of SDHB Mutation
por: Pacak, Karel, et al.
Publicado: (2022)

Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy
por: Uher, Ondrej, et al.
Publicado: (2023)

Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma
por: Vanova, Katerina Hadrava, et al.
Publicado: (2021)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

SAT305 Clinical Characteristics And Outcomes Of Patient With Metastatic Pheochromocytoma/Paraganglioma (PPGL) And Extreme Elevated Biochemistry
por: Prodanov, Tamara, et al.
Publicado: (2023)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma
por: Jha, Abhishek, et al.
Publicado: (2019)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
por: Vogel, Jennifer, et al.
Publicado: (2014)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy
por: Uher, Ondrej, et al.
Publicado: (2021)

Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity
por: Vit, Ondrej, et al.
Publicado: (2021)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization
por: Vit, Ondrej, et al.
Publicado: (2023)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma
por: Patel, Mayank, et al.
Publicado: (2022)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Mitochondrial complex II and reactive oxygen species in disease and therapy
por: Hadrava Vanova, Katerina, et al.
Publicado: (2020)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

A Predictive Nomogram for Early Death in Pheochromocytoma and Paraganglioma
por: Li, Huiyang, et al.
Publicado: (2022)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

RF21 | PSUN08 Morphologic or Molecular Imaging - Diagnostic Capabilities in von Hippel-Lindau related pheochromocytoma
por: Patel, Mayank, et al.
Publicado: (2022)

Metanephrine and normetanephrine associated with subclinical myocardial injuries in pheochromocytoma and paraganglioma
por: Yu, Yang, et al.
Publicado: (2022)

New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
por: Jhawar, Sakshi, et al.
Publicado: (2022)

Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background
por: Ullrich, Martin, et al.
Publicado: (2019)

High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma
por: Giubellino, Alessio, et al.
Publicado: (2014)

Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas
por: Brazda, Peter, et al.
Publicado: (2022)

Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
por: Nölting, Svenja, et al.
Publicado: (2019)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
por: Liu, Yang, et al.
Publicado: (2020)

The top 100 most-cited papers in pheochromocytomas and paragangliomas: A bibliometric study
por: Duan, Sai-Li, et al.
Publicado: (2022)

FGF21 Levels in Pheochromocytoma/Functional Paraganglioma
por: Klímová, Judita, et al.
Publicado: (2019)

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
por: Crona, Joakim, et al.
Publicado: (2018)

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas
por: Matlac, Dieter M., et al.
Publicado: (2021)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

Pheochromocytomas and secreting paragangliomas
por: Plouin, Pierre-François, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0jga7j9l3eladkcf5dv1tc5gv6